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Abstract
Purpose: Concurrent chemoradiation plays an integral role in the treatment of esophageal cancer. Proton beam radiation therapy has
the potential to spare adjacent critical organs, improving toxicity profiles and potentially improving clinical outcomes.
Methods and Materials: We evaluated the REG001-09 registry for patients undergoing proton radiation therapy for esophageal
cancer. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled.
Results:We identified 155 patients treated at 10 institutions between 2010 and 2019. One hundred twenty (77%) had adenocarcinoma and
34 (22%) had squamous cell carcinoma. One hundred thirty-seven (88%) received concurrent chemotherapy. The median delivered dose
was 50.51 Gy-equivalent (GyE; range, 41.4-70.1). Grade ≥3 toxicities occurred in 22 (14%) of patients and were most commonly
dysphagia (6%), esophagitis (4%), anorexia (4%), and nausea (2%). There were no episodes of grade ≥4 lymphopenia and no grade 5
toxicities. The average mean heart, lung, and liver doses and average maximum spinal cord dose were 10.0 GyE, 4.8 GyE, 3.8 GyE, and
34.2 GyE, respectively. For gastroesophageal junction tumors, 8% of patients developed acute grade ≥3 toxicity and the mean heart, liver,
right kidney, and left kidney doses were 10.5 GyE, 3.9 GyE, 0.4 GyE, and 4.9 GyE, respectively. Gastroesophageal junction location was
protective against development of grade≥3 toxicity on univariate (P = .0009) andmultivariate (P = .004) analysis.
Sources of support: This work had no specific funding.
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The data sets generated and analyzed during the present study are not
publicly available but are available from the corresponding author on rea-
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Conclusions: Proton beam radiation therapy affords excellent dosimetric parameters and low toxicity in patients with esophageal
cancer treated with curative intent. Prospective trials are underway investigating the comparative benefit of proton-based therapy.
© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Esophageal cancer is relatively rare but has one of
the worst prognoses among all malignancies. The Che-
moradiotherapy for Esophageal Cancer Followed by
Surgery Study (CROSS) established trimodality ther-
apy as the standard of care for resectable esophageal
cancer, with 5-year overall survival (OS) of 47% rep-
resenting a considerable improvement relative to his-
torical series.1-3 However, such treatment may incur
significant cardiopulmonary, hematologic, and postop-
erative complications that may predict poor out-
comes.4,5 Radiation therapy (RT) plays an integral
role in this treatment paradigm, but the proximity of
the esophagus to dose-limiting critical structures, such
as the heart and lung presents a unique challenge. To
date, a number of studies have demonstrated that
intensity modulated RT (IMRT) may result in a signif-
icant benefit relative to 3-dimensional conformal RT
(3DCRT) by virtue of an improved toxicity profile as
a result of more conformal dosimetry and superior
sparing of adjacent organs-at-risk.6-8
Proton beam therapy (PBT) has the potential to further
improve dose conformity and spare normal tissues.9
Indeed, the physical characteristics of particle therapy
offer the potential for improved target coverage while
reducing dose to surrounding critical structures compared
with photon-based therapy.10 In contrast to photon-based
therapy, proton therapy sharply deposits dose at the
Bragg peak, yielding a localized high-dose region around
the target volume without exit dose to significantly spare
nearby healthy tissue. Several retrospective studies have
demonstrated a clinical and dosimetric advantage with
this approach.11-13 Xi et al suggested an OS benefit with
the use of PBT compared with IMRT, and Lin et al sug-
gested that the clinical benefit of PBT may derive from
an improved cardiopulmonary toxicity profile.11,12 More
recently, a phase 2B trial comparing IMRT and PBT
demonstrated an improved toxicity profile with PBT with
similar clinical endpoints.14 In particular, this study used
a novel toxicity endpoint, total toxicity burden (TTB),
which encompassed 13 possible instances of 11 distinct
adverse events, which were either postoperative or
deemed secondary to chemoradiation. Before closure
upon activation of the NRG-GI006 phase 3 randomized
PBT versus IMRT trial, mean TTB was found to be lower
for PBT than IMRT, with similar rates of 3-year progres-
sion free survival and OS. Further prospective investiga-
tion is required before PBT can be considered a standard
of care. The present study is a multi-institutional prospec-
tive registry evaluation of patients receiving definitive
PBT for locally advanced esophageal cancers, with a
focus on acute toxicity and dosimetry profiles.
Methods and Materials
The REG001-09 trial is a prospective, multi-institu-
tional registry study of patients undergoing PBT; begin-
ning in 2017 patients treated with photon therapy alone
or in addition to PBT were also permitted to enroll. Writ-
ten informed consent was obtained from all patients
before they were enrolled on the registry study. Institu-
tional review board approval was granted for each of the
participating institutions.
The registry trial was queried for the subset of patients
undergoing PBT for esophageal cancer to the intact esoph-
agus. Patients were treated with pencil beam scanning
(PBS) or passive scattering/uniform scanning (PS). Patients
undergoing photon therapy were excluded. Only patients
treated to at least 41.4 dose unit Gy-equivalent (GyE)
were included in the present analysis (patients with limited
metastatic disease treated with definitive intent were
allowed per treating physician discretion). Patients receiv-
ing esophageal reirradiation were not eligible. Patient,
tumor characteristics, radiation treatment details, toxicity,
and dosimetric information were all collected.
Patients generally underwent 4-dimensional computed
tomography (CT) simulation with intravenous contrast.
Gross tumor volume was defined as all disease as seen on
positron emission tomography/computed tomography and
esophagogastroduodenoscopy, and clinical target volume
included all areas of potential disease spread. Optimal
beam arrangements were determined on a case-by-case
basis. The relative biologic effectiveness was set at 1.1 per
institutional standard of all participating institutions. GyE
was proton dose in Gy multiplied by relative biologic
effectiveness. Fractionation schemes were at the discretion
of participating institutions. Acute toxicity was physician-
graded and documented at on-treatment visits and at up to
3-month clinical follow-up. Follow-up beyond 3 months is
not reported in the present study. Toxicity was recorded
using the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0.
The actuarial rates of toxicity were calculated using the
Kaplan-Meier method, starting from the first day of radia-
tion. The log-rank test was used to analyze intergroup dif-
ferences. Univariable analysis was conducted using the
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Cox proportional hazards regression model, and prognostic
factors with univariate significance of P < .1 where further
tested in multivariate analysis to determine hazard ratios
(HR). Two-sample t tests were conducted to compare dosi-
metric means based on patient baseline characteristics. Sta-
tistical analyses were performed using R version 3.6.2.
Statistical significance was set to P < .05.
Results
Patient characteristics
In total, 161 patients signed consent forms and were
enrolled on the registry trial. A total of 155 patients were
treated to at least 41.4 GyE. These patients were treated
across 10 institutions between 2010 and 2019. The
median number treated per institution was 11 (range, 1-
39). Of the 155, 120 (77%) had adenocarcinoma, 34
(22%) had squamous cell carcinoma, and 1 (1%) had
mixed adenocarcinoma/neuroendocrine. Patient charac-
teristics are listed in Table 1. The logistics of surgery and
surgical postoperative toxicity were not collected on the
registry and are not reported herein. The vast majority of
patients underwent concurrent systemic therapy (88%).
Of patients receiving systemic therapy, 97 (71%)
received carboplatin/paclitaxel, 5 received capecitabine
(4%), 4 received paclitaxel/cisplatin/fluorouracil (3%), 4
received fluorouracil monotherapy (3%), 5 received cis-
platin/fluorouracil (4%), 6 received docetaxel-based regi-
mens (4%), 1 received leucovorin/fluorouracil/oxaliplatin
(1%), 1 received paclitaxel/ carboplatin /fluorouracil
(1%), and 13 received unknown regimens (9%). One hun-
dred fifteen (74%) had tobacco histories, 38 did not
(25%), and 2 had unknown status (1%).
Radiation and dosimetry
Ninety-three patients (60%) were treated with PBS, 53
were treated with PS (34%), and 9 (6%) were treated
with unknown technique. The median dose delivered was
50.51 GyE (range, 41.4-70.1). One hundred forty-nine
patients (96%) completed treatment as planned, whereas
2 stopped due to toxicity (2%), 1 stopped due to patient
preference (1%), 1 died due to reasons not related to
treatment toxicity (1%), and 2 stopped for other unspeci-
fied reasons (1%). Of those patients finishing treatment as
planned, 51 required a treatment break (34%). Twenty-
seven (18%) had a break due to equipment issues, 13
(9%) had a break per patient preference, and 11 (7%) had
a break due to toxicity (either radiation, systemic therapy,
or a combination). The average maximum spinal cord
dose was 34.2 GyE (range, 11.5-44.3 GyE), the average
mean heart dose was 10.0 GyE (range, 1.4-25.9), the
average mean total lung dose was 4.8 GyE (range, 1.4-
13.4), and the average mean liver dose was 3.8 GyE
(range, 0.59-16.7). When evaluating only patients with
gastroesophageal junction (GEJ) tumors, the average
mean heart dose was 10.5 GyE, the average mean liver
dose was 3.9 GyE, the average mean right kidney dose
was 0.4 GyE, and the average mean left kidney dose was
4.9 GyE. The presence of T3/T4 disease (versus T1/T2),
Table 1 Patient characteristics
Characteristic n = 155% (no.)
or median (range)












































Abbreviation: ECOG = Eastern Cooperative Oncology Group.
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N + disease (versus N0), or GEJ location were not associ-
ated with higher mean heart, mean lung, mean liver, or
maximum spinal cord doses by 2-sample t tests (P > .05
for all).
Toxicity
Acute toxicities are presented in Table 2. The most
common toxicities of any grade were radiation dermatitis
(101/155, 65%), fatigue (93/155, 60%), nausea (87/155,
56%), anorexia (66/155, 43%), esophagitis (62/155,
40%), and dysphagia (45/155, 29%). Grade ≥3 toxicities
included dysphagia (10/155, 6%), esophagitis (6/155,
4%), anorexia (6/155, 4%), nausea (3/155, 2%), esoph-
ageal pain (2/155, 1%), and radiation dermatitis (2/155,
1%). There was in addition one grade ≥3 episode of each
of the following: fatigue, pain, and neutropenia. There
were no episodes of grade 4 leukopenia. Postoperative
complications and long-term cardiopulmonary sequelae
were not comprehensively available. As depicted in
Fig. 1, the 3-month actuarial freedom from grade ≥3 tox-
icity was 81.8% (95% CI [confidence interval], 74.8%-
89.4%). Univariate and multivariate analysis were
Table 2 Treatment-related toxicity
Toxicity
CTCAE category CTCAE term Any grade% (no.) grade 3+% (no.)
Cardiac Atrial fibrillation 1% (1)
Gastrointestinal Diarrhea 19% (30)
Dry mouth 3% (5)
Dyspepsia 16% (25)
Dysphagia 29% (45) 6% (10)
Esophageal obstruction 1% (1)
Esophageal pain 16% (25) 1% (2)
Esophagitis 40% (62) 4% (6)
Oral mucositis 3% (4)
Nausea 56% (87) 2% (3)
Gastric obstruction 1% (1)
Stomach pain 1% (1)
Vomiting 21% (32)
General Fatigue 60% (93) 1% (1)
Noncardiac chest pain 1% (1)
Pain 23% (36) 1% (1)
Infections Stoma site infection 1% (1)
Injury/procedural Radiation dermatitis 65% (101) 1% (2)
Investigations Neutropenia 1% (1) 1% (1)
Lymphopenia 0 0
Thrombocytopenia 0 0
Weight loss 10% (15)
Metabolism Anorexia 43% (66) 4% (6)
Dehydration 17% (26)
Musculoskeletal Back pain 1% (1)
Nervous system Dizziness 1% (2)
Dysgeusia 3% (5)
Peripheral sensory neuropathy 4% (6)






Pharyngolaryngeal pain 1% (2)
Sore throat 2% (3)
Skin Erythema multiforme 3% (5)
Hyperpigmentation 3% (5)
Vascular Hypotension 1% (1)
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events (version 4).
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performed to determine prognostic factors for the devel-
opment of grade ≥3 toxicity (Table 3). The presence of
GEJ location was associated with lower rates of grade ≥3
toxicity on univariate (HR 0.074; 95% CI, 0.016-0.34;
P = .0009) and multivariate (HR 0.10; 95% CI, 0.02-
0.48; P = .004) analyses. The presence of T3/T4 disease
versus T1/T2 disease (P = .57) and N + disease versus N0
























Figure 1 Kaplan-Meier freedom from grade ≥3 toxicity from the start of radiation therapy.
Table 3 Univariate and multivariate analysis for development of grade ≥3 toxicity
Univariate Multivariate
Variable Level HR 95% CI P value Variable HR 95% CI P value
Age 1.05 1.003-1.10 .037 Age 1.05 0.96-1.14 .29
ECOG 1-3 vs 0 0.79 .31-2.04 0.63
Size, cm 1.23 .81-1.86 0.34
T stage T3/T4 vs T1/T2 0.77 .32-1.89 0.57
N stage N+ vs N0 0.98 .39-2.45 0.97
Dose, GyE 0.97 0.88-1.07 .57
Modality PBS vs PS 1.03 .42-2.54 0.95
Location GEJ vs other 0.074 .016-.34 0.0009 Location 0.10 .02-.48 0.004
Mean heart dose 0.81 0.62-1.05 .11
Mean lung dose 0.78 0.45-1.33 .36
Mean liver dose 1.1 0.89-1.35 .38
Maximum cord dose 1.27 0.95-1.70 .11
Abbreviations: CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; GEJ = gastroesophageal junction; HR = hazard ratio;
PBS = pencil beam scanning; PS = passive scattering.
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toxicity. In addition, the use of PBS versus PS technique
(P = .95) was not associated with lower rates of grade ≥3
toxicity.
Discussion
To our knowledge, this is the largest prospective
report of patients undergoing proton beam therapy for
esophageal cancer. We report very low rates of acute tox-
icity and dosimetric parameters, consistent with other
recently published particle-based series.14,15 Our acute
toxicity profile also compare favorably to acute events
during chemoradiation on the CROSS trial, despite the
fact that those patients only received 41.4 Gy.3 In particu-
lar, we report only a single patient with grade ≥3 hemato-
logical toxicity (1 of 155, 1%), compared with a 7% (12
of 171) rate of grade ≥3 hematological toxicity on the
CROSS trial. In terms of nonhematological toxicity, 14%
(22 of 155) of our patients experienced grade ≥3 toxicity,
compared with 13% on the CROSS trial.
The impetus for increasing conformality in esophageal
radiation planning stems from the central location of the
esophagus in the thorax and its proximity to the heart and
lungs. Although 3DCRT technically remains the stan-
dard-of-care, intensity modulated radiation therapy
(IMRT) is now commonly used based on retrospective
evidence suggesting dosimetric and clinical benefit. By
virtue of decreased cardiac dosing with IMRT, there is
suggestion that patients have lower cardiac morality with
IMRT that may translate to an overall survival advan-
tage.7,8 IMRT may also significant reduce the V10 (vol-
ume receiving 10 Gy), V20, and mean dose to the total
lung volume.6 With the increasing prevalence of proton
therapy centers in the United States, there is now a con-
certed effort to use particle-based therapies to further
improve outcomes via additional normal tissue sparing.
Until recently, these efforts were from single institu-
tions and retrospective in nature. In one of the initial
reports on PS proton beam therapy at MD Anderson,
patients treated to 50.4 GyE in 28 fractions experienced
low rates of grade 3 esophagitis (9.7%), dysphagia
(9.7%), nausea/vomiting (8.1%), radiation dermatitis
(3.2%), fatigue (8.1%), and anorexia (4.8%).15 There
were also 2 episodes of grade 5 toxicity. Our correspond-
ing toxicities compare very favorably to these results,
which could be attributed to the exclusive use of PS tech-
nique in that study, in contrast to the PBS used in a
majority of our patients. PBS uses magnets to “paint” the
target volume layer by layer, allowing for potentially
more conformal dose distributions.9 However, drawing
comparisons between retrospective series must be under-
taken with caution. Moreover, PBS did not significantly
predict for lower grade ≥3 toxicity on statistical analysis
(P = .95). Other retrospective series have similarly sug-
gested meaningful reductions in dose to heart, lung, and
liver afforded by proton therapy along with modest rates
of grade ≥3 toxicity.16
More recently, in a phase 2B randomized trial compar-
ing protons with IMRT, Lin et al demonstrated that
patients receiving proton therapy had improved TTB.14
TTB was created as a novel toxicity index to evaluate the
total patient experience throughout their treatment as an
alternative to more conventional National Cancer Insti-
tute Common Terminology Criteria for Adverse Events-
based methods. Three-year progression-free survival and
OS rates were similar on the study between the proton
and photon-based groups. For the PBT group, they
reported average mean lung, average mean heart, average
mean liver, and average maximum spinal cord doses of
4.8 Gy, 11.3 Gy, 2.4 Gy, and 38.3 Gy, respectively.
Among their IMRT patients, the respective values were
8.4 Gy, 19.8 Gy, 12.1 Gy, and 38.4 Gy. Our respective
values of 4.8 GyE, 10.0 GyE, 3.8 GyE, and 34.2 GyE are
similar to these parameters, and highlight the improve-
ment in heart, lung, and liver dosimetry when using pro-
tons. In general, 3DCRT therapy yields even higher
doses to organs-at-risk than IMRT, with mean heart doses
up to 28.3 Gy in 3DCRT series.7 Among the 11 distinct
adverse events encompassed by TTB, we report only a
single episode of atrial fibrillation (although follow-up
was limited, and our results are limited to acute toxicity).
There were no episodes of grade ≥4 lymphopenia in
our series, and only a single case of grade ≥3 hematologi-
cal toxicity. In general, lymphocyte counts decline during
chemoradiation, which in part is due to the extreme
radio-sensitivity of lymphocytes. Lymphocytes are the
most radiosensitive cell in the human body, with a D50
(dose required to kill 50% of the population) of approxi-
mately 1 Gy.17 Davuluri et al demonstrated that a grade 4
absolute lymphocyte count nadir was associated with
worse overall survival in patients with esophageal can-
cer.4 In that series, 59% of patients had a grade 3 absolute
lymphocyte count nadir and 27% of patients had a grade
4 nadir. The lower rates of lymphopenia observed with
proton therapy are likely secondary to lower integral dose
and thereby less dose to circulating blood cells and poten-
tially precursor blood cells in the bone marrow. Unfortu-
nately, bone marrow was not routinely contoured in the
present study. The lack of cytotoxic T lymphocytes in
these patients may weaken host defense,18 thus adversely
affecting clinical outcomes. Put together, the alleviation
of toxicity burden and reduction in lymphopenia nadir
offer 2 potential pathways via which proton therapy may
improve clinical outcomes in patients with locally
advanced esophageal cancer (NRG-GI006 protocol).
Among our patients, the presence of T3/T4 or
N + disease did not predict for the development of grade
≥3 toxicity, which suggests that with PBT, dose confor-
mity is achievable even in patients with very locally
advanced disease. Based on RTOG 9404, radiation dose
escalation beyond 50.4 Gy is not considered standard.2
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However, that trial was based on outdated radiation tech-
niques, was prematurely closed, and 7 out of 11 treat-
ment-related deaths occurred in patients receiving less
than 50.4 Gy. With improved technical capabilities, there
has recently been renewed interest in dose escalation,
particularly in patients who are not operative candidates.
In fact, more recent evidence suggests that there might be a
dose-response and benefit for dose-escalation.19 This is cur-
rently being investigated with a phase 1 dose-escalation
trial of neoadjuvant proton beam radiation therapy at the
University of Pennsylvania (NCT02213497). Moreover,
the ART DECO trial (NRT3532) is a randomized phase 3
trial comparing standard-dose (50.4 Gy) to high-dose (61.6
Gy via a simultaneous integrated boost) chemoradiation.
Preliminary results do not suggest a local control benefit
with dose-escalation as measured by 3-year local-progres-
sion free survival,20 although this has not been published in
manuscript form. Furthermore, our results also suggest that
distal esophageal location is protective against grade ≥3
toxicity. This is likely a result of normal esophageal physi-
ology, wherein the proximal portion of the esophagus is
more sensitive and less compliant than the distal portions.21
It is also possible that patients with GEJ tumors are more
likely to have comorbid gastroesophageal reflux, which
limits esophageal sensitivity along the entire tract of the
organ.22 Finally, GEJ tumors may better spare the heart and
lung, though we did not find improved dosimetry in this
analysis with GEJ tumors.
Shortcomings of this report includes incomplete infor-
mation on which patients underwent definitive esopha-
gectomy after chemoradiation. Accordingly, we do not
report clinical outcomes herein. In addition, we do not
report long-term toxicity and we are thus unable to cap-
ture potential late cardiopulmonary sequelae of treatment
and correlate this with our dosimetry data. Removing
patients receiving less than 41.4 GyE may have intro-
duced selection bias into our analysis. Moreover, because
toxicity was collected in radiation oncology departments,
hematological toxicity may be underreported. The popu-
lation presented is heterogeneous due to the multi-institu-
tional nature of this report and the fact that patients were
not treated on a strictly defined protocol. Conversely, this
represents the largest proton experience on dosimetry and
acute toxicity in patients with esophageal cancer to date
and is prospective in nature.
We conclude that treatment with proton-based therapy
with curative intent in patients with esophageal cancer
affords promising normal tissue sparing and rates of non-
hematological acute grade ≥3 toxicity that compare
favorably to photon-based historical controls, contribut-
ing to the growing body of evidence showing that PBT is
safe and feasible. The presence of distal esophageal loca-
tion predicts protection from acute grade ≥3 toxicity.
Prospective evaluation of the comparative efficacy of
proton therapy compared with photon-based therapy is
the basis for the ongoing NRG-GI006 study.
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